UBE3A reinstatement restores behaviorand proteome in an Angelman syndrome mouse model of imprinting defects.
Claudia Milazzo, Ramanathan Narayanan, Solveig Badillo and 9 others
PMID 40877933WHAT IT FOUND
In Angelman syndrome mice with imprinting defects, restoring UBE3A expression reversed motor, anxiety, and seizure deficits.
Antisense oligonucleotide treatment partially rescued behavior, improving nest building and tail suspension scores but not rotarod performance.
Key findings
01Embryonic transgenic overexpression of UBE3A in mICD mice completely reversed behavioral deficits and seizure susceptibility observed in the model.
02Neonatal treatment with UBE3A-ATS targeting antisense oligonucleotides (tASO) resulted in only a partial behavioral rescue, improving nest building and tail suspension immobility but failing to improve reverse rotarod or marble burying performance.
03Proteomic analysis showed that UBE3A reinstatement normalized dysregulated proteins and proteasome-related pathways in the cortex of mICD mice.
STILL TO COME
How it was doneWhat they found
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The study was conducted exclusively in mice; no human participants were involved. Behavioral readouts did not include sleep, neuronal activity, or learning and memory tests due to technical constraints. The underlying brain regions responsible for the observed behavioral changes in the tests are not known, limiting translational value. Some phenotypes, such as hind-limb clasping, were not replicated in all cohorts, suggesting variability. The ASO treatment was administered neonatally; efficacy in older mice or after symptom onset was not tested.
Declared interests
Funding was provided by Associazione Angelman, FROM, F. Hoffmann-La Roche Ltd., and the Angelman Syndrome Foundation.
The easy way to misread this
Do not interpret the partial behavioral rescue from antisense oligonucleotide treatment in mice as evidence that this therapy will fully reverse symptoms in human patients with Angelman syndrome, particularly motor deficits like those seen in the rotarod test which were not improved.